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1 List of abbreviations 
Α alpha 
°C degree Celsius 
µg microgram 
µl microliter 
µM micromolar 
Acta1 skeletal muscle alpha actin 
Acta2 smooth-muscle alpha actin 
Akt protein kinase B 
ANP atrial natriuretic peptide 
BNP brain natriuretic peptide 
cDNA complementary deoxyribonucleic acid 
CHO-IR Chinese hamster ovary cells overexpress human insulin receptor 
cIR-IGFRdKO mice with cardiac inducible knockout of insulin receptor and insulin-like 
growth factor 1 receptor 
cIRSdKO mice with cardiac inducible knockout of insulin receptor substrate 1 and 2 
Cops6 COP9 signalosome complex subunit 6 
dKO double knockout (cIR-IGFRdKO  and cIRSdKO) mice 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
ERK extracellular signal-regulated kinases 
g gram 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
Gja1 gap junction protein 
IGF insulin-like growth factor-1 
kb kilobase pairs 
kg kilogram 
KO cIR-IGFRdKO knockout mice 
M molar 
MAPK mitogen activated protein kinases 
mg milligram 
min minute 
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ml milliliter 
mm millimeter 
mM milimolar 
mRNA messenger ribonucleic acid 
Myh7 cardiac beta myosin heavy chain 
Myocd myocardin 
ng nanogram 
nM nanomolar 
NRCM neonatal rat cardiomyocytes 
p90RSK phosphorylated 90 kDa ribosomal S6 kinase 
Pdlim5 PDZ and LIM Domain 5 
PI3K phosphatidylinositol 3-kinase 
PMA phorbol 12-myristate 13-acetate 
qPCR quantitative polymerase chain reaction 
RSK ribosomal s6 kinase 
sec second 
SRE serum response element 
SRF serum response factor 
Tnni1 slow skeletal muscle troponin I 
Tnnt2 cardiac muscle troponin T 
Trim63 tripartite motif containing 63 
WT cIR-IGFRdKO wildtype mice 
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2 Zusammenfassung 
Sowohl Insulin als auch Insulin-like growth factor 1 (IGF) aktivieren vielfältige 
Signalkaskaden im Herzen, die für einen ausreichenden Stoffwechsel und eine gute Funktion 
unerlässlich sind. Die Signale regeln unter anderem Kontraktilität, Metabolismus, 
Hypertrophie und Autophagie der Herzmuskelzellen. Um die Auswirkungen einer 
ausgeschalteten Insulin und IGF Signalkaskade im Herzen zu untersuchen, wurden Mäuse mit 
induzierbarer, kardialer Null-Mutation verwendet. In einem Mausmodell wurde der 
Insulinrezeptor und IGF-Rezeptor ausgeschaltet, in einem anderen die Insulin-Rezeptor-
Substrate 1 und 2. Beide Mausmodelle (dKO) wiesen einen ähnlichen Phänotyp, der mit 
Herzinsuffizienz und erhöhter Mortalität assoziiert war, auf. In den Mausmodellen wurden eine 
veränderte Sarkomerstruktur und eine Herunterregulation von an der Herzstruktur beteiligten 
Genen gefunden. Es ist noch nicht abschließend geklärt, wie Insulin die Expression von 
Sarkomerproteinen beeinflusst und somit die kontraktile Funktion des Herzens aufrechterhält. 
 
Ziel dieser Arbeit war es, die Rolle der Insulin Signalkaskade bei der Regulation der Expression 
von Sarkomerproteinen zu untersuchen. 
 
Neonatale Ratten Kardiomyozyten (NRCM) wurden aus Wistar Ratten isoliert. Die NRCM 
wurden für 1 Stunde mit PD98059, einem ERK-Phosphorylierungsinhibitor, vorbehandelt und 
für 4, 24 oder 48 Stunden mit Insulin stimuliert. mRNA wurde isoliert und mit Hilfe von qPCR 
quantifiziert. 
Chinese Hamster Ovary Zellen mit Überexpression des Insulinrezeptors wurden mit einem 
Reportergenkonstrukt, das entweder Skelettmuskel alpha Actin (Acta1) oder glatte Muskel 
alpha Actin (Acta2) Promoter enthält, transfiziert. Anschließend wurden die Zellen für 24 
Stunden mit Insulin stimuliert und die Transkriptionsaktivität gemessen. 
In 8 Wochen alten, transgenen Mäusen wurde die kardiale Expression von Insulinrezeptor und 
IGF-Rezeptor ausgeschaltet. Eine Woche nach der Genausschaltung wurden die weiblichen 
und männlichen Mäuse mit Insulin stimuliert. Die Proteinexpression wurde mit Hilfe von 
Western Blots analysiert. 
 
Herzen aus Mäusen mit gleichzeitiger Null-Mutation (KO) des Insulinrezeptors und IGF-
Rezeptors wogen 15% weniger als Wildtyp (WT) Herzen. Außerdem war das Verhältnis vom 
Herzgewicht zum Körpergewicht in WT Mäusen im Vergleich zu KO Mäusen signifikant 
höher. Die kardiale Proteinexpression von Insulinrezeptor und IGF-Rezeptor war in KO 
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Mäusen reduziert. Insulinstimulation führte zu einer Phosphorylierung von Akt, die in KO 
Herzen weniger ausgeprägt war als in WT Herzen. Eine vorausgegangene Expressionsanalyse 
ergab, dass mehrere für Sarkomerproteine codierende mRNAs in dKO Mäusen 
herunterreguliert waren. 
Insulinstimulation der NRCM führte zu einem signifikanten Anstieg der Menge an Acta1 und 
Acta2 mRNA. ERK-Hemmung in den NRCM verhinderte die Phosphorylierung von ERK und 
RSK durch Insulinstimulation und hemmt möglicherweise die durch Insulin induzierte Acta1 
und Acta2 mRNA Expression. 
Ein unabhängiger Ansatz zur Überprüfung der Signalkaskade wurde unter Verwendung eines 
Zellkulturmodells und transkriptionellen Reporterkonstrukten angestrebt, um zu bestimmen, 
ob die Signalkaskade von Insulin den serum response factor (SRF) aktiviert und somit die 
Expression der Sarkomerproteine kontrolliert. Insulin hatte hier keine spezifische Wirkung auf 
die Acta1 und Acta2 Promotoraktivitäten. Das Ausmaß der Aktivierung von Acta1  und Acta2 
Promotoren durch die Insulinstimulation war ähnlich des eines Luciferaseplasmides mit einem 
minimalen Promotor. Transfektionen ohne Myocardin, einem Coaktivator von SRF, führten zu 
niedrigeren Promotoraktivitäten. 
 
Zusammenfassend betrachtet scheint die Insulinstimulation keine spezifische Wirkung auf die 
Acta1 und Acta2 Promotoraktivitäten durch einen SRF abhängigen Mechanismus zu haben. 
Allerdings deuten unsere Daten der mRNA Expression in NRCM darauf hin, dass Insulin eine 
Wirkung auf die Acta1 und Acta2 Expression hat. Ob dieser Effekt direkt oder indirekt ist, 
muss noch abschließend geklärt werden.      
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3 Abstract 
Insulin signaling and insulin-like growth factor-1 (IGF) signaling display pleiotropic effects in 
the heart, which are required for normal cardiac metabolism and function. Signal transduction 
regulates amongst others: contractility, metabolism, hypertrophy, and autophagy. To study the 
effects of a loss of insulin and IGF signaling in the adult heart, mice with cardiac inducible 
double knockout (dKO) of insulin receptor and IGF receptor or insulin receptor substrates 1 
and 2 have been generated previously. Both models display overlapping phenotypes with heart 
failure and increased mortality. dKO mice show sarcomeric disarray and downregulation of 
genes involved in cardiac structure. It is incompletely understood, how insulin signaling 
preserves contractile function by maintaining sarcomeric protein expression.  
 
The aim of the current study was to investigate the role of insulin signaling in the regulation of 
sarcomeric protein expression.  
 
Neonatal rat cardiomyocytes (NRCM) were isolated from Wistar rats and stimulated with 
insulin for 4, 24 or 48 hours. Furthermore, NRCM were pretreated for 1 hour with PD98059, 
an ERK phosphorylation inhibitor, and stimulated for 24 hours with insulin. mRNA was 
purified and quantified with qPCR.  
Chinese hamster ovary cells with overexpression of insulin receptor were transfected with 
reporter constructs containing skeletal muscle alpha actin (Acta1) or smooth-muscle alpha actin 
(Acta2) promoters. Cells were then treated with vehicle or insulin for 24 hours and 
transcriptional activity was monitored.  
A cardiomyocyte-restricted and doxycycline-inducible Cre expressing transgene was used to 
delete the insulin receptor and IGF receptor in 8-week-old mice. One week after knockout 
induction mice were stimulated with insulin or saline. Protein expression was analyzed with 
western blots. 
 
Hearts from mice lacking insulin receptor and IGF receptor (KO) weighed 15% less than 
wildtype (WT) hearts and the heart to body weight ratios were significantly higher in WT 
compared to KO mice in both sexes. Cardiac insulin receptor and IGF receptor protein 
expression was reduced in KO mice. Insulin stimulation led to Akt phosphorylation in the heart, 
which was partly reduced in KO. Previously, expression profiling revealed that several mRNAs 
coding for sarcomeric proteins were downregulated in dKO mice. 
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Insulin stimulation in NRCM led to a significant increase in Acta1 and Acta2 mRNA 
expression levels. ERK inhibition in NRCM prevented ERK and RSK phosphorylation after 
insulin stimulation, and may inhibit insulin induced Acta1 and Acta2 expression.  
To assess the signaling in an independent approach, a cell culture model and transcriptional 
reporter constructs were utilized to determine whether insulin signaling actives serum response 
factor (SRF) activity to control sarcomeric protein expression. Insulin stimulation did not show 
a specific effect on Acta1 and Acta2 promoter activities. The magnitude of Acta1 and, Acta2 
promoter activity after insulin stimulation was similar to that of a luciferase plasmid with a 
minimal promoter. Transfections without myocardin, a coactivator of SRF, led to lower 
promoter activities. 
 
In conclusion, insulin stimulation does not seem to show a specific effect on Acta1 and Acta2 
promoter activities through an SRF dependent mechanism. However, our NRCM mRNA 
expression data suggests that insulin has an effect on Acta1 and Acta2 expression. Whether 
this effect is direct, or indirect, remains to be definitively determined. 
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4 Introduction 
Cardiovascular diseases are the leading causes of death in Germany. Approximately 40% of all 
deaths are caused by chronic ischemic heart disease, acute myocardial infarction and heart 
failure  (Statistisches Bundesamt 2015). Heart failure is defined as the failure of the heart to 
adequately supply the body periphery with blood. The heart cannot ensure tissue supply with 
oxygen and substrates. Multiple heterogeneous pathophysiological mechanism were described 
as causes for heart failure (MacIver et al. 2013).  
One of the suggested mechanisms is a change in metabolism and signaling pathways caused 
by insulin resistance (Riehle und Abel 2016). Insulin resistance is a pathological condition in 
which cells are less sensitive to insulin stimulation than healthy cells. Insulin resistance is the 
most powerful predictor of future development of type 2 diabetes mellitus (Taylor 2012). 
Diabetes mellitus is associated with an increased risk of heart failure (Kannel et al. 1974) and 
the severity of insulin resistance correlates with the severity of heart failure (Swan et al. 1997). 
Furthermore, diabetic patients with cardiovascular disease present higher morbidity and 
mortality than nondiabetic patients (Mytas et al. 2009). It has been suggested, that insulin-
regulated transcription factors might be involved in the development of cardiovascular diseases 
(Muller-Wieland et al. 2001). 
 
4.1 Insulin and insulin signaling 
Langerhans cells from the pancreas produce proinsulin, which is processed in the Golgi 
apparatus by proteolytic cleavage to insulin. Cells secrete insulin based on the blood glucose 
level (Rassow et al. 2008). The main effect of insulin is the regulation of glucose metabolism 
in different cells. Liver, muscle and adipose tissue are the most sensitive organs to insulin. 
Furthermore, insulin plays a role in protein metabolism and cell growth, stimulating uptake of 
amino acids into cells and increasing protein biosynthesis (Dimitriadis et al. 2011). Besides its 
fast metabolic effects, insulin has long term effects on transcriptional activity. Several genes 
have been shown with insulin sensitive elements on their promoter regions. For a subset, insulin 
reduces transcription. For others, insulin enhances transcription (Mounier und Posner 2006). 
Insulin influences the regulation of more than 150 genes (O'Brien et al. 2001). This regulation 
is not completely understood.  
Insulin acts on its receptor, which belongs to the receptor tyrosine kinase family. Insulin 
receptor contains two extracellularly located alpha subunits and two membrane-spanning beta 
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subunits with tyrosine kinase activity. Binding of insulin promotes autophosphorylation and 
activates regulation of target proteins. Important phosphorylation targets are insulin receptor 
substrates 1 and 2 (Lee und Pilch 1994). 
Binding of insulin to its receptor activates two main pathways. On the one hand binding of 
insulin activates phosphatidylinositol 3-kinase (PI3K) cascade, which is mainly involved in 
metabolic changes. Protein kinase B (Akt) is activated by PI3K mediated phosphorylation. Akt 
mediates a variety of key reactions from the insulin pathway, for example transfer of insulin 
sensitive glucose transporter 4 in the plasma membrane (Siddle 2011). On the other hand 
binding of insulin activates mitogen activated protein kinases/extracellular signal-regulated 
kinases (MAPK/ERK) cascade, which is mainly involved in cell growth related gene 
expression. Activation of MAPK/ERK cascade influences a variety of transcription factors 
(Sutherland et al. 2013). One downstream target of ERK is phosphorylated 90 kDa ribosomal 
S6 kinase (p90 RSK). Activated p90 RSK influences mRNA translation and protein synthesis 
(Taha und Klip 1999). It has been shown, that defects in the MAPK/ERK cascade can be 
associated with decreased cellular insulin sensitivity (Zhang et al. 2011) and probably complex 
gene regulatory events (Muller-Wieland et al. 2001). 
Insulin binds to insulin-like growth factor 1 (IGF) receptor as well. IGF-receptor, a receptor 
tyrosine kinase, has a similar structure as the insulin receptor. Both receptors share common 
pathways. 
 
4.2 Insulin-like growth factor 1 and insulin-like growth factor 1 signaling 
IGF is mainly produced in the liver and secreted as a result of stimulation by growth hormone. 
IGF displays a high sequence similarity to proinsulin (Rinderknecht und Humbel 1978). IGF 
mediates anabolic effects on the organism and is growth-promoting and proliferating on almost 
every cell in the body (Yakar 2002). IGF binding to its receptor activates autophosphorylation 
and phosphorylation of insulin receptor substrates; hence the PI3K cascade and MAPK/ERK 
pathway are activated. Binding of insulin to IGF receptor and IGF to insulin receptor is 
possible, but associated with a lower affinity and potency (Rassow et al. 2008).  
IGF as well as insulin signaling display pleiotropic effects in the heart, which are required for 
normal cardiac metabolism and function. Both signaling pathways influence physiological and 
pathophysiological heart conditions (Riehle und Abel 2016). 
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4.3 Cardiac insulin and insulin-like growth factor 1 signaling 
Altered cardiac insulin and IGF signaling seem to play an important role in the development 
of heart failure. A healthy heart mainly uses free fatty acids as substrate. During advanced heart 
failure a substrate switch from fatty acids towards glucose occurs (Stanley und Chandler 2002). 
Insulin resistance inhibits this substrate switch, which has been suggested as adaptive response 
in the development of heart failure (Stanley et al. 2005). 
Insulin and IGF signaling activate PI3K. Acute activation of PI3K/Akt has cardioprotective 
effects in models of cardiac injury (Yao et al. 2014). It has been suggested, that cardioprotection 
is achieved by elevating glucose metabolism, an anti-apoptotic effect and controlling 
cardiomyocyte growth (Matsui und Rosenzweig 2005). Furthermore, insulin and IGF signaling 
activate MAPK/ERK pathway. ERK activation is involved in hypertrophic response as well as 
heart failure and seems to be cytoprotective (Zhang et al. 2003).  
To investigate insulin and IGF signaling in the heart, mice with cardiac inducible double 
knockout (dKO) of insulin receptor and IGF receptor or insulin receptor substrates 1 and 2 have 
been generated. Both models display overlapping phenotypes with heart failure and increased 
mortality. dKO mice show sarcomeric disarray and downregulation of genes involved in 
cardiac structure. In conclusion, loss of insulin and IGF signaling led to rapid disruption of 
sarcomeric structure and provide a critical mechanism for the development of heart failure 
(Riehle et al. 2015, unpublished results). 
 
4.4 Sarcomere structure and function 
Sarcomeres form the smallest unit of cardiac and striated skeletal muscles and are fundamental 
for their contraction. Long chains of sarcomeres are found in cardiomyocytes. To form a 
functional syncytium, cardiomyocytes are connected by gap junctions, which enable chemical 
communication and transfer electrical excitation between cells (Forbes und Sperelakis 1985). 
Each sarcomere contains multiple different structural proteins, whose arrangement give 
muscles their striated appearance under the light microscope. Thin filaments consisting of actin 
and thick filaments consisting of myosin are the contractile parts of a sarcomere (Behrends et 
al. 2010).  
Besides actin and myosin another central protein is the troponin complex. The troponin 
complex is an important regulator of cardiomyocyte contraction. Troponin T anchors the 
troponin complex to tropomyosin. Troponin I is the inhibitory region and maintains actin to 
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tropomyosin binding, preventing myosin to actin binding at low intracellular calcium 
concentration. Troponin C binds the switch region of troponin I in a calcium-dependent manner 
to activate contraction. The troponin complex releases the binding site from actin to myosin, 
when the cell is stimulated for contraction (Hwang und Sykes 2015). 
Proteins regulating sarcomere and cytoskeleton assembly are required for cardiac excitation-
contraction coupling as well. An example of such a protein is PDZ and LIM Domain 5 
(Pdlim5). Pdlim5 tethers protein kinases to the Z-line in striated muscles (Dixon et al. 2015). 
Alterations in sarcomeric protein composition lead to sarcomeric dysfunction with reduced 
cardiac pump function, which is often observed in heart failure (Hamdani et al. 2008). 
 
4.5 Working hypothesis of the current study 
Figure 1 shows the working hypothesis to investigate the connection between insulin signaling 
and regulation of sarcomeric protein expression in cardiomyocytes. As described above, insulin 
binds to its receptor on the cardiomyocyte´s cell surface and activates insulin signaling. 
MAPK/ERK pathway is activated and phosphorylates p90RSK. p90RSK contributes to the 
transcriptional activation of serum response factor (SRF). Myocardin is a transcriptional 
coactivator of SRF, they form a stable complex and bind to promoters on the DNA. Skeletal 
muscle alpha actin (Acta1) and smooth muscle alpha actin (Acta2) were described as SRF 
target genes. 
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Figure 1. Working hypothesis of connection between insulin signaling and regulation of sarcomeric 
protein expression in cardiomyocytes, insulin (yellow dots) binds to insulin receptors (green rectangles) 
on cell surface. Flash indicates activation of insulin pathway. Arrows indicate activation. 
Phosphorylated (p), extracellular-signal-regulated kinases (ERK1/2), phosphorylated 90 kDa ribosomal 
S6 protein kinase (p90RSK), serum response factor (SRF), myocardin (Myocd), skeletal muscle alpha 
actin (Acta1), smooth muscle alpha actin (Acta2), diagram of double-stranded DNA source: Wikipedia 
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5 Aim of the study  
Mice with cardiac inducible knockout of insulin receptor and insulin-like growth factor 1 
receptor or insulin receptor substrate 1 and 2 have been generated previously. Both models 
displayed overlapping phenotypes with heart failure and increased mortality. Expression 
profiling revealed that several mRNAs coding for sarcomeric proteins were downregulated in 
these mice. These observations suggest a connection between insulin signaling and regulation 
of sarcomeric protein expression in cardiomyocytes.  
How insulin signaling preserves contractile function by maintaining sarcomeric protein 
expression is incompletely understood. The aim of the current study was to take a closer look 
at insulin mediated regulation of sarcomeric protein expression through a serum response factor 
dependent mechanism. 
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6 Materials and methods 
6.1 Materials 
6.1.1 Buffers 
Table 1. Buffer recipes 
Buffer Recipe 
1x DNA extraction buffer 25 mM NaOH  
0.2 mM EDTA 
20x TAE buffer 800 mM TRIS base 
400 mM acetic acid 
20 mM sodiumEDTA 
1x RIPA buffer 50 mM TRIS-Cl pH 7.5 
150 mM NaCl 
0.2 mM Na2EDTA pH 8.0 
0.2 EGTA pH 7.5 
1 % NP-40 
1 % sodium deoxycholate 
2.5 mM sodium pyrophosphate 
20x MOPS buffer 1 M MOPS 
1 M TRIS base 
2% SDS 
0.02 M Na2EDTA 
10x transfer buffer 0.25 M TRIS 
1.92 M glycine 
20x TBS  0.2 M TRIS base 
1.5 M NaCl 
TBS/T 1xTBS 
0.1 % tween-20  
pH 7.6 with HCl 
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6.1.2 Primers 
Table 2. Primer sequences 
  
Use Target 5’-3’ sequence 
genotyping Cre forward  TGC CTG CAT TAC CGG TCG ATG 
reverse   CCA TGA GTG AAC GAA CCT GGT CG 
rtTA forward  GTC GCT AAA GAA GAA AGG GAA ACA C 
reverse   TTC CAA GGG CAT CGG TAA ACA TCT G 
qPCR Acta1 forward  CCT GTA TGC CAA CAA CGT CA 
reverse   CTC GTC GTA CTC CTG CTT GG 
Acta2  forward  GTC CCA GAC ATC AGG GAG TAA 
reverse   TCG GAT ACT TCA GCG TCA GGA 
Cops6 forward  TGA CTG GGA GTG TTT CCG TC 
reverse   GAG CCC CAA TCA CCT GCA TAG 
Gja1  forward  ACA GCG GTT GAG TCA GCT TG 
reverse   GAG AGA TGG GGA AGG ACT TGT 
Myh7 forward  AGG AGC AAC AGG AGG ACT TCA 
reverse   CTC TGC ATT GGT GGG ATT GGT 
ANP forward  GAG TGG ACT AGG CTG CAA CA 
reverse   CAC ACC ACA AGG GCT TAG GA 
BNP forward  TTT GGG CTG TAA CGC ACT GAA 
reverse   AAA GAG ACC CAG GCA GAG TCA 
Pdlim5 forward  TGA GAC AGA CTA CTA CGC CC 
reverse   TCC CAG AGC TTC CAG ATA CA 
Tnni2 forward  TTC GGA GGG TGC GTA TGT CT 
reverse   GTC CCG TTC CTT CTC AGT GT 
Tnnt1 forward  AAC AAT GCC TGT GGT TCT TCC 
reverse   TGT GCT CTA CAA CCG CAT CA 
Trim63 forward  GTG TGA GGT GCC TAC TTG CTC 
reverse   GCT CAG TCT TCT GTC CTT GGA 
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6.1.3 Kits 
Table 3. Kits 
Kit Company 
Direct-zol™ RNA MiniPrep  Zymo Research 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 
Pierce Primary Cardiomyocyte Isolation Kit Thermo Fisher Scientific 
PureLink Quick Plasmid Miniprep Kit Invitrogen 
Plasmid Maxi Kit Qiagen 
Dual-Luciferase® Reporter Assay System Promega 
 
6.1.4 Antibodies 
Table 4. Primary and secondary antibodies 
Primary GAPDH (14C10) Cell Signaling, Rabbit #2118 
 α-tubulin Sigma, T5168, Mouse 
 phospho-Akt (Ser473) Cell Signaling,  Rabbit #9271 
 Akt (pan) (40D4) Cell Signaling, Mouse #2920 
 phospho-p44/42 MAPK (Thr202/Tyr204) Cell Signaling, Rabbit #9101 
 p44/42 MAPK (Erk1/2) (3A7) Cell Signaling, Mouse #9107 
 phospho-p90RSK (Ser380) (D5D8) Cell Signaling, Rabbit  #12032 
 RSK1/RSK2/RSK3 (32D7) Cell Signaling, Rabbit #9355 
cloning Myocardin gccactgtgctggatgccaccATGACACTCCTGGGGTCTG 
ggtggaattctgcagatTTACCACTGCTGTAAGTGGAG 
SRF gccactgtgctggatgccaccATGTTACCGAGCCAAGCTG 
ggtggaattctgcagatTCATTCACTCTTGGTGCTG 
Acta1 tacgcgtgctagcccCCTCTAGGTCCCAACAGTTC 
gcagatctcgagcccCAGGTTTTTATATAGTCCCGG 
Acta2 tacgcgtgctagcccCTCTTTTCTTGTCTTTTAAAGGAATTG 
gcagatctcgagcccCTTGCTCTGATCCCCTCC 
Cloning primers include lowercase backbone-specific sequence and uppercase insert-specific sequence. 
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 SRF (D71A9) XP Cell Signaling, Rabbit #5147 
 Myocardin R&D Systems, 4028, Mouse #355521 
 insulin receptor β (L55B10) Cell Signaling, Mouse mAb #3020 
 IGF-I receptor β (111A9) Cell Signaling, Rabbit #3018 
Secondary goat anti-rabbit IgG Thermo Fisher, Alexa Fluor® 680  
 goat anti-mouse IgG Thermo Fisher, Alexa Fluor® 680  
 
6.1.5 Cell culture 
Chinese hamster ovary cells overexpress human insulin receptor and were a kind gift of Morris 
F. White, Harvard Medical School Boston (Backer et al. 1992). 
 
Table 5. Cell culture media 
Media Company 
DMEM/F12 Gibco 
Penicillin-Streptomycin (10,000 Units/ml) Gibco 
Trypsin-EDTA (0.05%), phenol red Gibco 
Fetal Bovine Serum - Premium Atlanta Biologicals 
DMEM, low glucose Gibco 
 
6.1.6 Plasmids 
pcDNA3.1 plasmid was derived from Invitrogen and confers ampicillin resistance for selection 
in bacteria. The reporter plasmid pGL3_basic was derived from Promega and confers an 
ampicillin resistance as well. Promoters of Acta1 and Acta2 were cloned into the SmaI 
digestion site upstream of the firefly luciferase coding sequence. pRL-SV40 and CMV vectors 
were derived from Promega and encoded renilla luciferase. 
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6.2 Methods 
6.2.1 Housing conditions and mouse colony 
Transgenic mice and Wistar rats were housed on a 12 hour light/12 hour dark cycle at 22°C 
with free access to food (2020X Teklad Global Soy Protein-Free Extruded Rodent Diet) and 
water. All experiments were performed in accordance with protocols approved by the Carver 
College of Medicine of the University of Iowa. 
The doxycycline inducible cardiac specific insulin-like growth factor 1 receptor and insulin 
receptor deficient mice (cIR-IGFRdKO) were generated by developing compound transgenic 
mice harboring a tet-on Cre (purchased from Jackson lab, strain number 6234), an rtTA under 
the control of the αMHC promoter and two floxed IGF receptor as well as insulin receptor 
alleles. All mice were back-crossed to the C57/BL6 genetic background.  
For the induction 8-week-old cIR-IGFRdKO mice were intraperitoneal injected with 
doxycycline (doxycycline hyclate, sigma) 4mg/kg body weight and kept on doxycycline chow 
(1g/kg) for 1 week. At the age of 9 week the mice were sacked. After anesthesia 0.01 U/g body 
weight of insulin or saline was injected into the inferior vena cava. After 10 minutes the tissues 
were collected and immediately frozen in liquid nitrogen until further use. The right tibia was 
collected as well, freed from tissue in 1 M NaOH at 90°C for 20 minutes and the length 
measured. 
 
6.2.2 Genotyping of mice 
To obtain DNA from each mice an ear punch was taken, digested in 80 µl DNA extraction 
buffer at 98°C for 1 hour and afterwards 80 µl of 40 mM TRISHCl pH 5.5 were added.  
 9.5 µl  water 
 10 µl 2x ChoiceTaq master mix 
 0.5 µl primer mix 
 2 µl DNA 
Mix was prepared and ran with the protocol from table 6. The resulted product was separated 
on 2% agarose gel in 1x TAE buffer with ethidium bromide for about 20-30 minutes under a 
voltage of 120 volt. A picture was taken with the VWR Gel Imager.   
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Table 6. PCR protocol 
Function Temperature Time 
initial denaturation 94°C 3 min 
 
40 cycles 
denaturation 94°C 45 sec 
annealing 54°C for Cre, 62°C for rtTA 30 sec 
extension 72°C 30 sec 
final hold 72°C 2 min 
cool down 4°C until use 
 
6.2.3 Quantitative polymerase chain reaction 
Sample preparation 
NRCM were directly lysed with a cell scraper in TRIzol (life technologies). Heart tissue pieces 
were homogenized in the TissueLyserII (Qiagen) in TRIzol. The purification of mRNA was 
performed with the Direct-zol™ RNA MiniPrep from Zymo Research based on the company’s 
protocol, which includes a DNAse I treatment.   
The purity control and concentration measurements of mRNA samples were performed with 
the NanoDrop2000. 2 µl of each sample were analyzed. The ratios of absorbance at 260/280 as 
well as 260/230 were used to assess the purity of mRNA and DNA.  
The mRNA was transcribed in cDNA with the High-Capacity cDNA Reverse Transcription 
Kit. mRNA was mixed with 2x Reverse Transcription master mix from the kit and run in a 
thermocycler based on the company’s protocol. Afterwards, a standard curve was generated 
and nuclease-free water added to each sample. 
Primer design and melting curve 
Primer Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to design the 
quantitative polymerase chain reaction (qPCR) primers with the following inclusions: 
amplicon length approximately 75–150 base pairs, primer 18–24 nucleotides in length and free 
of internal secondary structure, primer pairs with compatible melting temperatures and 
approximately 50% guanine-cytosine content. To allow differentiation between amplification 
of the desired cDNA and potential contaminating genomic DNA an exon/intron selection was 
preferred. The designed primers were ordered at Integrated DNA Technologies (IDT 
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Coralville). To test the primer’s specificity for cDNA a regular PCR with cDNA and genomic 
DNA for each primer was performed. 
A melting curve was produced at the end of 40 qPCR cycles. The temperature was raised slowly 
and fluorescence continuously measured. Primers with one melting curve peak were used. 
qPCR and Quantification 
Samples were pipetted in triplicate in a 384 well plate:  
 4.5 µl diluted cDNA 
 0.25 µl 4 µM forward primer 
 0.25 µl 4 µM backward primer 
 5 µl Power SYBR® Green master mix 
 
Table 7. qPCR protocol 
Function Temperature Time 
initial denaturation 95°C 10 min 
 
40 cycles 
denaturation 95°C 15 sec 
annealing 60°C 1 min 
extension 72°C 1 min 
melting curve 60° - 95°C 0.05°C increase every sec 
cool down 4°C until use 
 
The measuring instrument (QuantStudio™ 7 Flex Real-Time PCR System) generated an 
amplification plot by plotting fluorescence signal against the cycle numbers.  
QuantStudio™ Software V1.2 for QuantStudio™ 6 and 7 Flex was used. The software 
automatically set a threshold. Threshold cycle reflected the cycle number at which the 
fluorescence generated within a reaction crossed the threshold. The software averaged triplicate 
of each sample and calculated under use of the standard curve quantity means. For 
normalization of expression levels between experiments COP9 signalosome complex subunit 
6 (Cops6) was used as a housekeeping gene. 
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6.2.4 Western blot 
Sample preparation and BCA 
NRCM were directly lysed in RIPA buffer with Halt™ Protease and Phosphatase Inhibitor 
Cocktail. Heart tissue pieces were homogenized in the TissueLyserII (Qiagen) in RIPA buffer 
with Halt™ Protease and Phosphatase Inhibitor Cocktail. The total protein concentration was 
determined with the Thermo Scientific Pierce BCA Protein Assay Kit. A standard curve of 
bovine serum albumin and the samples were pipetted in triplicate into a 96 well plate and 
measured by the Epoch Microplate Spectrophotometer. The results were analyzed with the 
Gen5 Data Analysis software. Based on the concentration, the amount of protein necessary was 
calculated and mixed with NuPAGE® LDS sample buffer (4x), 2-mercaptoethanol (2.5%) and 
filled up to 20 µl with RIPA-Buffer. The samples were heated to 70°C for 10 minutes for 
denaturation.  
Western Blot 
The sample and a molecular weight marker (Odyssey® Protein Molecular Weight Marker (10-
250 kDa)) were loaded in the wells of a NuPAGE™ Novex™ 4-12% Bis-Tris Gel. The gel 
was run in 1x MOPS buffer with NuPAGE® Antioxidant for 1 hour at 200 volt to separate the 
samples based on their size. Proteins were moved from the gel to a polyvinylidene fluoride 
membrane (IPFL00010, Immobilon-FL) by electric field. Transfer conditions were 0.2 ampere 
for 2 hours in 1x transfer buffer with 20% methanol at 4°C.  
Membranes were blocked for 1 hour in 5% bovine serum albumin TBS/T, incubated overnight 
in primary antibody (dilution 1:1000), washed three times 5 minutes each with TBS/T, 
incubated for 1 hour with secondary antibody (dilution 1:20000) and washed again.  
For detection of the fluorescent secondary antibody the Odyssey CLx Infrared Imaging System 
from LI-COR was used. The image was analyzed with the Image Studio Lite software. Protein 
contents were normalized by Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or α-
tubulin. 
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6.2.5 Cell culture 
Neonatal rat cardiomyocytes 
Neonatal rat cardiomyocytes (NRCM) were isolated on day 3 of Wistar rat pups with the 
Thermo Scientific Pierce Primary Cardiomyocyte Isolation. The dishes for cultivation were 
coated with collagen type 1 rat tail. Two neonatal rat hearts were pooled in one tube and isolated 
based on the kit’s protocol. NRCM were kept in an incubator with 5% CO and 37°C humidified 
air. As recommended 10 % heat inactivated fetal bovine serum and 1 % penicillin-streptomycin 
were added to media. 24 hours after isolation media were changed and growth supplement was 
added. On day 4 or 5 after isolation the NRCM were starved in serum free, low glucose DMEM 
media and treated on the next day. 
CHO-IR cells and transfection 
Chinese hamster ovary cells overexpress human insulin receptor (CHO-IR) were cultured in 
DMEM/F-12 media with 10 % fetal bovine serum and 1 % penicillin-streptomycin on 10 cm 
dishes in an incubator with 5% CO and 37°C humidified air. For cell culture passing 
Trypsin/EDTA 0.05% solution was used. The splitting was done every 2-3 days with a 1:10 
dilution. 
For transfection 100000 CHO-IR cells (Z Series Coulter Counter) were plated in each well 
from a 6 well dish in serum free DMEM/F-12 media. Cells were transfected with 
Lipofectamine 2000 in a ratio of 1:3. 350 ng SRF or an empty pcDNA3.1 plasmid, 350 ng 
myocardin or an empty pcDNA3.1 plasmid and 350 ng Acta1 or Acta2 or an empty pGL3_basic 
plasmid and 0.35 ng of SV40 or CMV renilla plasmid were mixed for each well. A total amount 
of 100 µl serum free media with about 1 µg of DNA and 3 µl of Lipofectamine was transfected 
into each well. 
 
6.2.6 Cloning 
Gibson assembly 
pcDNA3.1 was digested with EcoRV and pGL3_basic with SmaI. SRF was amplified from 
mouse heart cDNA and myocardin from the Addgene Plasmid #46033. The promoter regions 
of Acta1 and Acta2 were amplified from genomic mouse DNA.  
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These reactions were performed with the Q5 High-Fidelity 2x master mix: 
 12.5 µl Q5 High-Fidelity 2x master mix 
 2.5 µl 10 µM forward and reverse primer (designed by NEBbuilder assembly tool) 
 1 µl template DNA (100 ng of cDNA or genomic DNA) 
 9 µl nuclease-free water 
 
Table 8. High-Fidelity PCR protocol 
Function Temperature Time 
initial denaturation 98°C 30 sec 
 
30 cycles 
denaturation 98°C 10 sec 
annealing myocardin and SRF 63.5°C, Acta1 and Acta2 61°C 20-30 sec/kb 
extension 72°C 1 min 
final extension 72°C 2 min 
cool down 4°C until use 
 
HiFi DNA assembly protocol from NEBbuilder assembly tool was used for Gibson assembly. 
Gibson assembly reaction was set up with 10 µl of 2x assembly master mix, the calculated 
amount of insert and backbone and filled up with water to 20 µl. This mix was incubated at 
50°C for 30 minutes. 
Transformation of competent cells 
NEB 5alpha competent E. coli cells were transformed with 2 μl of the assembled product, 
placed for 30 minutes on ice, heat shocked for 30 seconds at 42°C and placed back on ice for 
2 minutes. 950 µl SOC medium at room temperature was added to each tube and incubated for 
1 hour at 37°C while shaking.  
20 grams lysogeny broth were stirred into 1 liter of water and 15 grams of bacto agar were 
added. This solution was autoclaved and cooled down to 55°C to add 100 µg/ml ampicillin, 
used for selection of transfected cells. 20 ml were poured into 100x15 mm petri dishes, they 
were stored at 4°C until use. Prior to use a lysogeny broth agar plate was warmed up to 37°C. 
100 µl of the transformed cells were spread on the plate and incubated overnight at 37°C. 
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Analysis of insert 
Amplification of the cloned fragment was screened by PCR, plasmids from that colony were 
purified with the Quick Plasmid Miniprep Kit (Invitrogen). 200 ng purified plasmids were 
digested with restriction enzyme. Acta1 in pGL3-basic and myocardin in pcDNA3.1 were 
digested with BglIII, Acta2 in pGL3_basic with AseI and SRF in pcDNA3.1 with BlpI. After 
one hour digestion a distinct fragment pattern was shown on 1% agarose gel.  
Plasmid were Sanger sequenced at the Iowa Institute of Human Genetics with the Applied 
Biosystems Model 3730 (48-capillary) and Model 3730xl (96-capillary) DNA Sequencers. The 
resulted fluorescent peak trace showed the correct order of nucleotides.  
DNA from the colony with confirmed insert was isolated by using the Qiagen Maxi Kit. 
 
6.2.7 Luciferase Assay 
As described in the cell culture section, CHO-IR cells were transfected with two different types 
of luciferase vectors. The resulting transcription products were firefly and renilla luciferase, 
which were able to convert luciferin into oxyluciferin under light emission. The Dual-
Luciferase Assay System was used from Promega and measurements were carried out in the 
GloMAx Promega luminometer. The transfected CHO-IR cells were lysed in 100 µl of passive 
lysis buffer. 10 µl of this lysate was pipetted in triplicates to the 96well plate for luciferase 
activity measurement. First 50 µl of luciferase assay reagent was added to each well and the 
firefly light emission monitored for 5 seconds. After a 5 seconds delay, 50 µl of stop & glow 
reagent was added and the renilla light emission monitored for 5 seconds. Firefly luciferase 
activity was normalized to renilla luciferase acticity, which was used as control of transfection 
efficiency into CHO-IR cells. 
 
6.2.8 Statistical analysis 
The mean, standard deviation and t-test were calculated with Microsoft Excel and expressed as 
mean values ± standard deviation with n denoting the number of experiments. GraphPad Prism 
5 was used for the creation of graphics. Data are expressed as fold change or relative expression 
to control values. Differences were considered statistically significant at a p value of <0.05, 
this is indicated by an asterisk.    
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7 Results 
7.1 Characteristics of dKO mice (Riehle et al. 2015) 
Riehle et al. used cardiac inducible double knockout mice of insulin receptor and insulin-like 
growth factor 1 receptor (cIR-IGFRdKO) or insulin receptor substrate 1 and 2 (cIRSdKO) to 
study the effects of a loss of insulin signaling in the adult hearts. Both models displayed cardiac 
dysfunction and sarcomeric disarray as early as one week after knockout induction. Expression 
profiling revealed that several mRNAs coding for sarcomeric proteins were downregulated in 
dKO mice, decreased mRNA levels of genes involved in cardiac structure as early as three days 
(fast skeletal muscle troponin I, slow skeletal muscle troponin T, gap junction protein (Gja1), 
myosin light chain 1, skeletal muscle alpha actin (Acta1), and smooth-muscle alpha actin 
(Acta2) by 52-82%, p<0.05 each). Accordingly, electron micrographs revealed loss of 
sarcomeric integrity as early as 3 days post-deletion of insulin receptor and insulin-like growth 
factor 1 (IGF) receptor or insulin receptor substrates 1 and 2. In general the sarcomeric structure 
was less organized. The M- and Z-lines were diffused degraded and less intense. The 
intercalated disks were pulling apart. 
 
7.2 cIR-IGFRdKO mice displayed reduced heart weight 
Table 9 lists the male and table 10 the female body, lung and heart weights and tibia length of       
9-week-old wildtype (WT) and cIR-IGFdKO (KO) mice, one week after knockout induction. 
Body and lung weights were not different between WT and KO, neither the lung to body weight 
ratios, in both sexes. KO hearts weighed 15% less than WT hearts in both sexes. Female mice 
presented with lower body weight and lower heart weight compared to males. Nevertheless, 
heart to body weight ratios from both sexes were similar for the same genotype. 
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Table 9. Body weight (BW), lung weight (LW), heart weight (HW) and tibia length of 9-week-old male 
cardiac inducible double knockout of insulin receptor and insulin-like growth factor 1 receptor (KO) 
and wildtype mice (WT), one week after knockout induction.  
variable WT KO p value 
BW (g)  22.8 ± 1.8  23.0 ± 2.6   0.8802 
LW (mg) 146.8 ± 6.4  151.8 ± 13.8  0.3335 
HW (mg) 106.7 ± 7.1  91.3 ± 8.8  0.0007 
Tibia length (mm) 16.5 ± 0.4  16.4 ± 0.4  0.6547 
BW/Tibia length 1.39 ± 0.09 1.40 ± 0.13  0.7638 
LW/BW 6.45 ± 0.27  6.63 ± 0.39  0.2682 
HW/BW 4.68 ± 0.20   3.98 ± 0.21  0.0000 
Mean ± standard deviation of mean, n=10 
 
Table 10. Body weight (BW), lung weight (LW), heart weight (HW) and tibia length of 9-week-old 
female cardiac inducible double knockout of insulin receptor and insulin-like growth factor 1 receptor 
(KO) and wildtype mice (WT), one week after knockout induction.  
variable WT KO p value 
BW (g)  16.3 ± 1.6 17.3 ± 1.6 0.3761 
LW (mg) 123.2 ± 12.8 125.8 ± 9.5 0.7232 
HW (mg) 81.8 ± 8.2 70.2 ± 5.8 0.0286 
Tibia length (mm) 15.6 ± 0.4 15.7 ± 0.3 0.6839 
BW/Tibia length 1.05 ± 0.10 1.10 ± 0.09 0.3807 
LW/BW 7.55 ± 0.29 7.32 ± 0.54 0.4286 
HW/BW 5.02 ± 0.26 4.08 ± 0.22 0.0001 
Mean ± standard deviation of mean, n=6 
 
7.3 Cardiac insulin receptor and IGF receptor protein expression was reduced 
one week after knockout induction in cIR-IGFRdKO mice 
Figure 2 shows cardiac insulin receptor and IGF receptor protein expression in 9-week-old 
mice one week after knockout induction. The insulin receptor and IGF receptor levels were 
decreased in KO compared to WT in both sexes. 
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Figure 2. Cardiac protein expression in 9-week-old cardiac inducible double knockout of insulin 
receptor and insulin-like growth factor 1 receptor (KO) and wildtype mice (WT), one week after 
knockout induction, (A) level of insulin receptor (IR) in male KO and WT, (B) level of insulin-like 
growth factor receptor (IGFR) in male KO and WT, (C) level of IR in female KO and WT, (D) level of 
IGFR in female KO and WT, values were normalized to α-tubulin and presented as mean ± standard 
deviation of mean. *p < .05 compared to WT, n=10 for male, n=6 for female 
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7.4 Reduced Acta1 mRNA expression in female cIR-IGFRdKO mice 
Figure 3 shows mRNA expression levels of sarcomeric proteins and heart failure markers in            
9-week-old female cIR-IGFRdKO mice one week after knockout induction. A significant 
increase was seen in the mRNA expression levels of atrial natriuretic peptide (ANP) and brain 
natriuretic peptide (BNP). mRNA expression of sarcomeric proteins showed a significant 
reduction in Acta1. Acta2 (p=0.23), Gja1 (p=0.06), PDZ and LIM domain 5 (Pdlim5) (p=0.24) 
and cardiac muscle troponin T (Tnnt2) (p=0.15) expression levels remained unchanged. 
Cardiac beta myosin heavy chain (Myh7) and slow skeletal muscle troponin I (Tnni1) presented 
with high variability. 
 
 
Figure 3. mRNA expression levels of sarcomeric related genes and heart failure markers in 9-week-old 
female cardiac inducible double knockout of insulin receptor and insulin-like growth factor 1 receptor 
one week after knockout induction, skeletal muscle alpha actin (Acta1), smooth muscle alpha actin 
(Acta2), cardiac beta myosin heavy chain (Myh7), gap junction protein (Gja1), PDZ and LIM domain 
(Pdlim5), slow skeletal muscle troponin I (Tnni1), cardiac muscle troponin T (Tnnt2), atrial natriuretic 
peptide (ANP) and brain natriuretic peptide (BNP), values were normalized to Cops6 and presented as 
mean ± standard deviation of mean. *p < .05 compared to wildtype, n=4 
 
7.5 Insulin stimulation led to increased Acta1 and Acta2 expression in NRCM 
Figure 4 shows mRNA expression levels from sarcomeric related genes (Acta1, Acta2, Myh7, 
Gja1, Pdlim5, Tnni1, Tnnt2) in NRCM after insulin stimulation. Insulin stimulation was 
checked for efficiency assessing tripartite motif containing 63 (Trim63) downregulation 
(p<0.05 for 4 and 24 hours, p=0.12 for 48 hours). Overall both actin genes showed the biggest 
increase: Acta1 was significantly upregulated in all stimulated NRCM and Acta2 after 24 and 
48 hours of stimulation.  
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Figure 4. mRNA expression levels of sarcomeric related genes in NRCM after (A) 4 hours, (B) 24 
hours and (C) 48 hours of 500 nM insulin stimulation, tripartite motif containing 63 (Trim63) as insulin 
stimulation control, skeletal muscle alpha actin (Acta1), smooth muscle alpha actin (Acta2), myosin 
heavy chain (Myh7), gap junction protein (Gja1), PDZ and LIM domain (Pdlim5), troponin I (Tnni1), 
troponin T (Tnnt2), values were normalized to Cops6 and presented as mean ± standard deviation of 
mean. *p < .05 compared to unstimulated control, n=3 for (A) and (C), n=5 for (B) 
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Figure 5. Protein expression in 100 nM insulin or 1 µM phorbol 12-myristate 13-acetate (PMA) 
stimulated NRCM, open bars indicate control, black bars insulin and grey bars PMA stimulated, 
dimethylsulfoxide (DMSO) was vehicle for 10 µM ERK inhibition (PD98059) and PMA treatment (A) 
level of phophorylated Akt at Ser473 to total Akt protein, myocardin (Myocd) and serum response 
factor (SRF) checked for presense and not quantified (B) level of phosphorylated ERK 1/2 at 
Thr202/Tyr204 to total ERK protein, (C) level of phosphorylated p90RSK at Ser380 to total RSK 
protein, values were normalized to GAPDH or α-tubulin and presented as mean ± standard deviation of 
mean for no (-) and PD98059 treatment or presented as mean for DMSO. n=4 for - and PD98059 
treatment, n=2 for DMSO 
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7.6 ERK inhibition prevented ERK and RSK phosphorylation, and may inhibit 
insulin induced Acta1 and Acta2 expression 
Figure 5 shows phosphorylated to total protein expressions in insulin or phorbol 12-myristate 
13-acetate (PMA) stimulated NRCM with or without ERK inhibition. Presence of myocardin 
and serum response factor (SRF) in NRCM was shown. PMA stimulation led to an increased 
level of phosphorylated ERK 1/2 at Thr202/Tyr204 to total ERK protein and an increased level 
of phosphorylated p90RSK at Ser380 to total RSK protein. PMA is an activator of protein 
kinase C and was more efficient in ERK and RSK activation than insulin stimulation. Insulin 
stimulation led to an increased level of phophorylated Akt at Ser473 to total Akt protein, an 
increased level of phosphorylated ERK 1/2 at Thr202/Tyr204 to total ERK protein and an 
increased level of phosphorylated p90RSK at Ser380 to total RSK protein. ERK inhibition in 
NRCM completely abolished insulin-induced ERK and RSK activation. Insulin-induced Akt 
activation was unaffected by ERK inhibition. 
Figure 6 shows mRNA expression levels of Acta1 and Acta2 in insulin stimulated NRCM with 
or without ERK inhibition. Insulin stimulation led to an increase in Acta1 and Acta2 mRNA 
expression. However, the increase was blunted with ERK inhibition. The results are difficult 
to interpret give the strong decrease in basal mRNA expression of Acta1 and Acta2 with ERK 
inhibition. Acta1 expression within one replicate was equal with or without ERK inhibition. 
Acta2 expression within one replicate was higher without ERK inhibition. This indicates a high 
degree of variability in the experiments which requires additional replicates to definitively 
determine the role of ERK in insulin activated Acta1 and Acta2 expression. 
 
 
Figure 6. mRNA expression of (A) skeletal muscle alpha actin (Acta1) and (B) smooth muscle alpha 
actin (Acta2) in NRCM after 24 hours of 500 nM insulin stimulation with or without 10 µM ERK 
inhibition (PD98059), open bars indicate control, solid bars insulin stimulated, values were normalized 
to Cops6 and presented as mean, n=2 
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7.7 Insulin stimulation led to ERK and RSK phosphorylation in CHO-IR cells 
Figure 7 shows phosphorylated to total protein expressions in insulin-stimulated Chinese 
hamster ovary cells overexpress human insulin receptor (CHO-IR). Insulin stimulation led to 
increased level of phosphorylated ERK 1/2 at Thr202/Tyr204 to total ERK protein and an 
increased level of phosphorylated p90RSK at Ser380 to total RSK protein. Higher insulin 
concentration did not lead to further increase of ERK and RSK activation. Maximal activation 
was already achieved with 100 nM. Furthermore, the maximal extent of phosphorylation was 
before 30 minutes, because the earlier time point of 15 minutes showed a higher ERK and RSK 
activation than the later one. 
 
 
Figure 7. Protein expression in insulin stimulated CHO-IR cells after 15 and 30 minutes, open bars 
indicate 100 nM insulin, grey bars 500 nM insulin, black bars 1000 nM insulin, (A) level of 
phosphorylated ERK 1/2 at Thr202/Tyr204 to total ERK protein, (B) level of phosphorylated p90RSK 
at Ser380 to total RSK protein, values were normalized to GAPDH, n=1 
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7.8 Acta1 and Acta2 promoter activities were not stimulated by insulin 
Figure 8 shows Acta1 and Acta2 promoter activities 24 hours after transfection into CHO-IR 
cells. PMA treatment served as positive control for the setup, inducing SRF activity and leading 
to elevated promoter activities. Transfection without myocardin led to reduced promoter 
activities compared to baseline and served as negative control, because SRF can only bind to 
DNA with its coactivator myocardin. Acta1 promoter insert showed in all treatments about 25 
times higher activity than pGL3_baisc. Acta2 promoter insert showed in all treatments about 5 
times higher activity than pGL3_basic. Acta1 and Acta2 promoter activities did not show a 
specific effect in response to insulin. Insulin stimulated Acta1 promoter activity and Acta2 
promoter activity in a similar strength as a luciferase plasmid with minimal promoter 
(pGL3_basic). 
Figure 9 shows Acta1 and Acta2 promoter activities 24 hours after transfection into CHO-IR 
cells. This measurement, normalized to CMV renilla luciferase, obtained similar results to the 
promoter activities from Figure 8, where firefly activity was normalized to SV40 renilla 
luciferase. Transfection without myocardin led to reduced promoter activities compared to 
baseline. Insulin or IGF stimulation had no effect on promoter activities in cells lacking 
myocardin. Activities were similar to untreated cells without myocardin. Insulin as well as IGF 
stimulation of transfected cells led to increased promoter activities. Acta1 promoter activity 
was about 25 times and Acta2 promoter activity about 4 times higher than pGL3_basic activity. 
Acta1 and Acta2 promoter activities did not show a specific effect in response to insulin and 
IGF. Insulin as well as IGF stimulated Acta1 promoter activity and Acta2 promoter activity in 
a similar strength as a luciferase plasmid with minimal promoter (pGL3_basic). While there 
seems to be a general activation in promoter activity, this may not be promoter activity at all. 
Because the pathways being activated regulate protein synthesis, the luciferase activity could 
be simply an increase in protein synthesis. Therefore, the increase in pGL3 basic could be due 
to increased protein synthesis and not SRF/Myocardin activity. However, Figure 9B suggests 
that myocardin is necessary for the induction in pGL3 basic activity. Again, interpretation of 
these results is difficult given the small sample size. This requires further replication to 
determine if Acta1 and Acta2 promoter activities induced by insulin or IGF are generic or 
dependent on SRF. 
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Figure 8. Empty pGL3_basic, skeletal muscle alpha actin (Acta1) and smooth muscle alpha actin 
(Acta2) promoter activities 24 hours after transfection into CHO-IR cells, the promoters were 
cotransfected with overexpression plasmids for serum response factor and myocardin (Myocd). (A) 
normalized to pGL3basic no treatment, (B) normalized to each promoter no treatment, black bars 
indicate empty pGL3_basic vector, open bars Acta1 promoter and grey bars Acta2 promoter activity 
with no treatment (-) or 500 nM insulin stimulation or transfection without (wo) Myocd or 
dimethylsulfoxide (DMSO) treatment or 1 µM phorbol 12-myristate 13-acetate (PMA) stimulation, 
promoter firefly luciferase activities were normalized to SV40 renilla luciferase and presented as mean. 
n=2 for - and insulin, n=1 for wo Myocd, DMSO and PMA 
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Figure 9. Empty pGL3_basic, skeletal muscle alpha actin (Acta1) and smooth muscle alpha actin 
(Acta2) promoter activities 24 hours after transfection into CHO-IR cells, the promoters were 
cotransfected with overexpression plasmids for serum response factor and myocardin (Myocd). (A) 
normalized to pGL3basic no treatment, (B) normalized to each promoter no treatment, black bars 
indicate empty pGL3_basic vector, open bars Acta1 promoter and grey bars Acta2 promoter activity 
with no treatment (-) or 500 nM insulin stimulation or 100 nM insulin-like growth factor 1 (IGF) 
stimulation or transfection without (wo) Myocd or wo Myocd or wo Myocd and insulin stimulation or 
wo Myocd and IGF stimulation, promoter firefly luciferase activities were normalized to CMV renilla 
luciferase and presented as mean. n=2 for pGL3_basic and Acta1 with -, insulin stimulation and wo 
Myocd, n=1 for everything else 
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7.9 Insulin stimulation had no effect on ERK and RSK phosphorylation in WT 
and cIR-IGFRdKO mice in both sexes 
Figure 10 shows phosphorylated to total cardiac protein expression in insulin stimulated and 
control 9-week-old male cIR-IGFRdKO and WT mice, one week after knockout induction. The 
basal and insulin-induced levels of phophorylated Akt at Ser473 to total Akt protein were 
higher in WT compared to KO hearts. Insulin stimulation had no effect on phosphorylated ERK 
1/2 at Thr202/Tyr204 to total ERK protein or phosphorylated p90RSK at Ser380 to total RSK 
protein. 
 
 
Figure 10. Cardiac protein expression in 9-week-old male cardiac inducible double knockout of insulin 
receptor and insulin-like growth factor 1 receptor (KO) and wildtype mice (WT), one week after 
knockout induction, after 10 minutes of insulin or saline injection into the inferior vena cava, open bars 
indicate saline treatment, black bars insulin treatment, (A) level of phophorylated Akt at Ser473 to total 
Akt protein, (B) level of phosphorylated ERK 1/2 at Thr202/Tyr204 to total ERK protein, (C) level of 
phosphorylated p90RSK at Ser380 to total RSK protein, values were normalized to α-tubulin and 
presented as mean ± standard deviation of mean. n=5 
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Figure 11 shows phosphorylated to total cardiac protein expression in insulin stimulated and 
control 9-week-old female cIR-IGFRdKO and WT mice, one week after knockout induction. 
Females obtained similar results as males. Insulin stimulation led to Akt phosphorylation, 
which was partly reduced in KO mice. However, insulin stimulation had no effect on 
phosphorylation from ERK or RSK. 
 
 
Figure 11. Cardiac protein expression in 9-week-old female cardiac inducible double knockout of 
insulin receptor and insulin-like growth factor 1 receptor (KO) and wildtype mice (WT), one week after 
knockout induction, after 10 minutes of insulin or saline injection into the inferior vena cava, open bars 
indicate saline treatment, black bars insulin treatment, (A) level of phophorylated Akt at Ser473 to total 
Akt protein, (B) level of phosphorylated ERK 1/2 at Thr202/Tyr204 to total ERK protein, (C) level of 
phosphorylated p90RSK at Ser380 to total RSK protein, values were normalized to GAPDH and 
presented as mean ± standard deviation of mean. n=3 
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8 Discussion 
In the current study, mice with cardiac inducible double knockout of insulin receptor and 
insulin-like growth factor 1 receptor (cIR-IGFRdKO) presented with reduced heart weight and 
signs of heart failure. The biggest change in mRNA expression of sarcomeric proteins was 
observed with skeletal muscle alpha actin (Acta1) and smooth muscle alpha actin (Acta2). 
Expression of these genes was reduced in cIR-IGFRdKO mice and increased in insulin 
stimulated neonatal rat cardiomyocytes (NRCM). This lends support to the notion that insulin 
can regulate the expression of Acta1 and Acta2. Acta1 and Acta2 seem to be serum response 
factor (SRF) targets in a myocardin dependent manner. However, insulin stimulation does not 
seem to show a specific effect on Acta1 and Acta2 promoter activities through an SRF 
dependent mechanism. 
 
Female cIR-IGFRdKO mice showed upregulation of atrial natriuretic peptide (ANP) as well as 
brain natriuretic peptide (BNP) coding genes one week after knockout induction, indicating 
heart failure development (Sergeeva und Christoffels 2013, Yoshimura et al. 2001). Previous 
studies have shown impaired cardiac function in transgenic mice lacking insulin receptor 
systemically. Mice with cardiac-specific knockout of insulin receptor showed reduced ejection 
fraction (Belke et al. 2002, Riehle et al. 2015). Combined deficiency of insulin receptor and 
IGF receptor in cardiac and skeletal muscle results in death from heart failure within the first 
month of life. In terms of cardiac function, insulin receptor seems to be more important than 
IGF receptor (Laustsen et al. 2007). Insulin signaling has been found to preserve contractile 
function by maintaining sarcomeric protein expression in the adult heart (Riehle et al. 2015). 
 
We could show that female cIR-IGFRdKO mice showed a significant reduction in Acta1 
mRNA expression one week after knockout induction. Expression levels of Acta2, gap junction 
protein and troponin T remained unchanged. In contrast to our results, Laustsen et al. described 
upregulation of Acta1 and troponin I in hearts from muscle-specific insulin receptor and IGF 
receptor knockout mice (Laustsen et al. 2007). These experiments were performed in a 
constitutive knockout model of muscle-specific insulin and IGF receptor. Therefore, insulin 
and IGF signaling were deleted from the beginning of life.  Insulin signaling seems not to be 
necessary for prenatal growth and metabolic control in rodents, but for postnatal fuel 
homeostasis (Kitamura et al. 2003). Thus, the entire body adapts postnatally to systematic 
metabolic disturbances in a constitutive knockout model. These side effects can confound 
experimental results. Use of inducible and tissue-specific knockout models could be 
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advantageous to check specific roles of insulin signaling on adult cardiomyocyte`s function 
and metabolism.  
Downregulation of several genes involved in cardiac structure has been described in                        
cIR-IGFRdKO mice as well as in mice with cardiac inducible double knockout of insulin 
receptor substrates 1 and 2 (cIRSdKO) (Riehle et al. 2015). Besides other genes, Riehle et al. 
have found downregulation of Acta1, Acta2, gap junction protein and troponin T in                  
cIR-IGFRdKO male mice. Differences to our results might be caused by different sexes of  
cIR-IGFRdKO mice or different time points of gene expression measurements after knockout 
induction. We used female cIR-IGFRdKO mice one week after knockout induction and Riehle 
et al. male cIR-IGFRdKO mice three days after knockout induction.  
Conditional gene knockout methods are often used to model human diseases (Doetschman und 
Azhar 2012). cIR-IGFRdKO mice are a model for the cardiac effect of type 2 diabetes in 
patients. Naturally, humans do not have a knockout of insulin receptor, but type 2 diabetic 
patients are characterized by insulin resistance and relative insulin deficiency (American 
Diabetes Association 2009). Type 2 diabetic patients showed impaired autophosohorylation of 
insulin receptor from abdominal skeletal muscles (Maegawa et al. 1991), which is probably 
accompanied by intracellular insulin signaling deficiency. Gene expression profiling from 
skeletal muscle of patients with poorly controlled type 2 diabetes revealed downregulation of 
Acta1, Acta2, myosin heavy chain, troponin I and troponin T (Sreekumar et al. 2002). 
Altogether, these results match to the downregulation of several mRNAs coding for sarcomeric 
proteins in models lacking insulin signaling.  
 
Riehle et al. revealed loss of sarcomeric integrity in electron micrographs from cIR-IGFRdKO 
and cIRSdKO mice (Riehle et al. 2015). Previous studies found similar results. Laustsen et al. 
described abnormalities in the organization of cardiac sarcomeres in muscle-specific insulin 
receptor and IGF receptor knockout mice (Laustsen et al. 2007). Electron micrographs of 
cardiomyocytes from diabetic rats revealed disruption of banding patterns and separation at 
intercalated disks. Insulin treatment was able to recover banding pattern and intercalated disks 
partially (Thompson 1988). Taken together, these models present similar results regarding 
sarcomeric disarray to the animals used in this work. 
 
Sarcomeres are key components of cardiomyocytes and cardiomyocytes are main components 
of the heart. Therefore, they play a crucial role in determination of heart size. In this study, 
hearts from female and male cIR-IGFRdKO mice weighed 15% less than wildtype (WT) 
hearts. Similar results were found in comparable animal models. Significant reduction in heart 
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weight was shown in cardiac-specific insulin receptor knockout mice as well as muscle-specific 
insulin receptor and IGF receptor knockout mice (Belke et al. 2002, Laustsen et al. 2007). 
Insulin signaling has been described to play an important role in the regulation of 
cardiomyocytes size (Shioi et al. 2002). We assessed the effect of insulin stimulation on insulin 
signaling in cIR-IGFRdKO hearts. Basal and insulin-induced levels of phosphorylated to total 
Akt protein were reduced in cIR-IGFRdKO mice compared to WT. Stimulation of insulin 
receptor and IGF receptor is known to activate the PI3K/Akt pathway (Siddle 2011). 
Transgenic mice with cardiac overexpression of PI3K or Akt presented with larger hearts and 
increased cardiomyocyte cell size (Shioi et al. 2000, Condorelli et al. 2002). Furthermore, 
overexpression of Akt rescued the small cardiac phenotype from mice lacking cardiac insulin 
receptor (Shiojima et al. 2002). This suggests that reduced cardiac Akt phosphorylation in    
cIR-IGFRdKO mice might be a cause for reduced heart weight found.  
We did not check which cell line contributed to the significant reduction in heart weight, but it 
is presumably due to cardiomyocytes since the KO is specific to that cell type. Laustsen et al. 
described reduced cardiomyocytes cell size without increased interstitial fibrosis in muscle-
specific insulin receptor and IGF receptor knockout mice (Laustsen et al. 2007). Belke et al. 
described decreased cardiomyocyte areas, but no difference in cardiac collagen content in 
cardiac-specific insulin receptor knockout mice (Belke et al. 2002). Therefore, a significant 
reduction in heart weight from cIR-IGFRdKO mice may result from reduction in 
cardiomyocyte cell size. Downregulation of genes involved in cardiac structure potentially 
support this hypothesis. However, the effect of insulin signaling on regulation of sarcomeric 
protein expression is not known. 
 
Insulin has been found to activate the mitogen activated protein kinases/extracellular signal-
regulated kinases (MAPK/ERK) signaling cascade (Sutherland et al. 2013), which activates the 
phosphorylated 90 kDa ribosomal S6 kinase (p90RSK) through phosphorylation. MAPK/ERK 
cascade and RSK family are involved in cell growth related gene expression (Anjum und Blenis 
2008). Thus, we measured insulin stimulated ERK1/2 and p90RSK phosphorylation in hearts 
of cIR-IGFRdKO mice. Insulin stimulation had no effect on cardiac phosphorylation of 
ERK1/2 and p90RSK. In contrast to our results, insulin-stimulated ERK1/2 phosphorylation 
has been shown in skeletal muscle (Rui et al. 2001), aortae (Symons et al. 2009), liver and fat 
of mice (Tomilov et al. 2011). Furthermore, insulin-mediated p90RSK phosphorylation was 
described in skeletal muscle of mice (Grzelkowska-Kowalczyk und Wieteska 2005). Higher 
ERK1/2 and p90RSK phosphorylation compared to our results could be due to tissue specific 
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differences in insulin signaling pathways. More likely, our insulin stimulation into the inferior 
vena cava of cIR-IGFRdKO mice might have been too short or our dose too low to activate the 
insulin signaling cascade fully. To address the ERK1/2 and p90RSK phosphorylation we used 
NRCM to evaluate the effect of insulin stimulation. In this study, insulin activated Akt, ERK1/2 
and p90RSK by phosphorylation in NRCM. Other studies showed equivalent results regarding 
insulin-induced Akt phosphorylation (Mellor et al. 2014) as well as ERK1/2 phosphorylation 
in NRCM (Morisco et al. 2007).  
 
As described above, loss of insulin signaling in adult cardiomyocytes of transgenic mice caused 
a decrease in mRNA expression levels of sarcomeric proteins. Accordingly, insulin stimulation 
in NRCM is likely to increase mRNA expression levels of sarcomeric proteins. We saw an 
upregulation of Acta1 and Acta2 mRNA expression in insulin stimulated NRCM. Previously, 
insulin and IGF have been suggested to regulate cardiac growth (DeBosch und Muslin 2008). 
Insulin and IGF may activate the MAPK/ERK as well as the PI3K/Akt pathway, which both 
stimulate protein synthesis and inhibit protein breakdown (Heineke und Molkentin 2006). 
Shiojima et al. saw an insulin-induced cardiomyocyte hypertrophy in NRCM (Shiojima et al. 
2002). IGF stimulation induced hypertrophy in NRCM and increased mRNA levels for Acta1, 
myosin light chain and troponin I (Ito et al. 1993). Hence, our insulin administration on NRCM 
probably induced hypertrophy and growth-related upregulation of sarcomeric proteins. This is 
probably because of some indirect effect though since our promoter activity studies did not 
show activation. 
We assessed the contribution of the MAPK/ERK signaling cascade in insulin-mediated 
regulation of sarcomeric protein expression. ERK inhibitor completely abolished insulin-
induced ERK1/2 and p90RSK activation in NRCM. Similar results were obtained from other 
groups. Studies showed ERK1/2 inhibition through the same inhibitor in NRCM (Zhai et al. 
2007, Ruppert et al. 2013). Furthermore, the same inhibitor abolished insulin-induced ERK1/2 
phosphorylation and p90RSK activity in human skeletal muscle cells (Kotova et al. 2006).  
In this study, insulin stimulation led to an increase in Acta1 and Acta2 mRNA expression. 
Inhibition of ERK blunted that increase. The tremendous effect of ERK inhibition on basal 
expression makes it difficult to interpret the data. It may be impossible to overcome that level 
of inhibition with any stimulus that would increase Acta1 or Acta2 expression. Therefore, the 
concentration of PD98059 may need to be titered to find a concentration that inhibits ERK 
activity but does not have such a profound effect on basal gene expression. However, 
experiments with ERK inhibitor in NRCM revealed that ERK1/2 is required for sarcomeric 
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organization after hypertrophy induction (Clerk et al. 1998). Ruppert et al. reported attenuation 
of phenylephrine induced cardiomyocyte hypertrophy by ERK inhibition (Ruppert et al. 2013). 
Further experiments with phenylephrine added as a positive control could aid in interpretation 
of the current results. The profound effect of ERK inhibition of basal expression of Acta1 and 
Acta2 does support the idea that MAPK/ERK signaling is an important regulator of cardiac 
hypertrophy and involved in sarcomeric integrity. Impaired cardiac insulin signaling in         
cIR-IGFRdKO mice might be a cause for sarcomeric disarray found. As mentioned above, 
MAPK/ERK cascade activates p90RSK which has been found to contribute to the 
transcriptional activation of SRF (Anjum und Blenis 2008). While we see evidence in both 
NRCMs and CHO-IR cells that insulin activates the MAPK/ERK to p90RSK pathway, 
activation of SRF remains murky. 
 
SRF has been found to regulate the expression of contractile proteins required for proper 
assembly and function of cardiomyocytes. Besides Acta1 and Acta2, myosin heavy chains, 
myosin light chains, troponin C and troponin T were described as SRF targets (Miano et al. 
2007). Cardiac-specific deletion of SRF in embryos results in lethal cardiac defects (Parlakian 
et al. 2004). Experiments with SRF-null neonatal cardiomyocytes revealed defects in the 
structure of the contractile apparatus in electron micrographs (Balza und Misra 2006). 
Consistent with the embryonic phenotypes, adult hearts lacking SRF show highly disorganized 
sarcomeres and rapid progression to heart failure (Parlakian et al. 2005). These studies showed 
similar phenotypes compared to cIR-IGFRdKO and cIRSdKO mice including sarcomeric 
disarray and heart failure. To test the hypothesis that lack of cardiac insulin signaling led to 
decreased SRF activity, followed by downregulation of several sarcomeric proteins, we 
measured Acta1 as well as Acta2 promoter activity. We overexpressed SRF and its 
transcriptional co-activator myocardin in a cell culture model, but did not find a specific effect 
of insulin stimulation on Acta1 or Acta2 promoter activity. The change that you see in Acta1 
could be explained by a 2-fold induction in "activity" of promoter elements in the plasmid 
backbone. Even though, we overexpressed SRF and myocardin, experiments were performed 
in a heterologous cell system. Therefore our used CHO-IR cells might not have all of the 
transcriptional regulators that are present in cardiomyocytes.  In contrast to our results, insulin 
stimulated a serum response element (SRE) luciferase reporter gene approximately nine fold 
in Chinese hamster ovary cells stably expressing high levels of insulin receptor (Yamauchi und 
Pessin 1994). SRE is the binding site for SRF in promoter regions of target genes and contains 
the CArG box sequence (Huet et al. 2005). The difference in insulin stimulated luciferase 
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reporter activity could be due to the portion of the sequence upstream of the promoter. We used 
a long promoter region from Acta1 as well as Acta2. Yamauchi et al. used a short promoter 
region of the c-fos gene (Yamauchi und Pessin 1994). Differences in length or promoter 
sequence, especially in the CArG box region, could have led to changes in SRF transcriptional 
activity.  
 
It has been shown that in canine cardiac myoblasts insulin stimulation enhances SRF-SRE 
binding activity through activation of myocardin (Madonna et al. 2014). Insulin increased 
myocardin transcripts and protein levels, which may account for the activation of myocardin-
dependent SRF-SRE binding (Madonna et al. 2014). In this study, transfections without 
myocardin led to markedly repressed Acta1, Acta2, and minimal promoter activity. 
Furthermore, insulin stimulation had no effect on promoter activities. Previously, it has been 
shown that myocardin is unable to activate SRF-dependent promoters in embryonic stem cells 
lacking SRF (Wang et al. 2002). Furthermore, transfection without myocardin did not activate 
SRF-dependent promoter regardless of increasing SRF amounts (Wang et al. 2001). These 
results highlight the importance of myocardin as co-activator of SRF. SRF can only bind to 
DNA and activate transcription in the presence of myocardin effectively (Du et al. 2003). We 
could show that transfection with SRF and myocardin led to highly increased activity of Acta1 
promoter and increased activity of Acta2 promoter compared to a minimal promoter. In 
accordance with our results actin genes have been described as SRF target genes (Charvet et 
al. 2006, Miano et al. 2007, Parlakian et al. 2005, Zhang et al. 2001, Balza und Misra 2006). 
Gene microarray analysis from SRF-null neonatal cardiomyocytes revealed a huge decrease in 
Acta1 expression level and decrease in Acta2 expression level compared to control 
cardiomyocytes (Balza und Misra 2006). Based on the described expression levels and 
measured promoter activities, SRF seems to have a stronger influence on Acta1 gene 
expression than on Acta2 gene expression. However, we failed to demonstrate a specific 
induction in Acta1 and Acta2 promoter activity in response to insulin. 
 
Limitations of the study 
There are some limitations of this study. The first limitation concerns the low number of 
replicates and samples, especially in many of the transcription activity assays. Furthermore, 
experiments were performed in NRCM and CHO-IR cells to test a connection between insulin 
signaling and regulation of sarcomeric protein expression observed in adult mice 
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cardiomyocytes. Therefore, it is difficult to transfer results between these systems and 
conclusions are preliminary.   
To determine if Acta1 and Acta2 promoter activities induced by insulin or IGF are generic or 
dependent on SRF alternative experiments could be performed. There are new luciferase 
constructs in which the half-life of the protein is greatly reduced. This gives a more accurate 
read out of transcriptional activity versus the steady state levels of mRNA and protein. 
Constructs could be made with the SRF sites in the Acta1 and Acta2 promoters mutated. 
Furthermore, SRF could be knocked down in NRCM and checked if the induction of Acta1 
and Acta2 are reversed. 
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9 Conclusion 
In the current study, mice with cardiac inducible double knockout of insulin receptor and 
insulin-like growth factor 1 receptor (cIR-IGFRdKO) presented with reduced heart weight and 
signs of heart failure. The biggest change in mRNA expression of sarcomeric proteins was 
observed with skeletal muscle alpha actin (Acta1) and smooth muscle alpha actin (Acta2). 
Expression of these genes was reduced in cIR-IGFRdKO mice and increased in insulin 
stimulated neonatal rat cardiomyocytes. This lends support to the notion that insulin can 
regulate the expression of Acta1 and Acta2. Acta1 and Acta2 seem to be serum response factor 
(SRF) targets in a myocardin dependent manner. However, insulin stimulation does not seem 
to show a specific effect on Acta1 and Acta2 promoter activities through an SRF dependent 
mechanism in in vitro transcription assays. The non-specific effect requires other approaches 
to definitively test our hypothesis. 
 
Outlook 
To investigate the connection between insulin signaling and regulation of sarcomeric protein 
expression in cardiomyocytes further studies could be conducted. Additional work could focus 
on the identification of insulin-dependent transcriptional programs that regulate sarcomeric 
integrity in adult hearts. One potential relevant family of transcription factors could be forkhead 
box O proteins. Forkhead box O proteins transcription factors have been shown as downstream 
targets of the insulin pathway involved in cardiac hypertrophy and could thus play an essential 
role in maintaining sarcomere structure and functional integrity in the adult heart.  
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